On June 12, WuXi Biologics rose 3.21% in regular trading, trading at 30.84 HKD/share, with turnover of 358 million HKD. The rebound comes as the company continues its aggressive share repurchase program while the broader Life Sciences Tools & Services sector recovers from last week's sell-off triggered by the US Department of Defense's 1260H list update.

The company repurchased 3.388 million shares on June 11 for approximately 99.82 million HKD, marking the latest in a series of consecutive buybacks. Since early June, cumulative repurchases have exceeded 599 million HKD across eight transactions this year, as part of the broader 400 million USD buyback plan announced earlier. Guotai Junan International recently maintained its Outperform rating with a target price of 54.49 HKD, implying approximately 77% upside, while CICC maintained a 48 HKD target price.

The sector showed broad-based strength, with WuXi XDC up 4.49%, XtalPi up 4.1%, GenScript Biotech up 2.7%, Insilico Medicine up 2.32%, and WuXi AppTec up 2.11%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)